Bristol-Myers Squibb (BMY)

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...

As management tackles key issues head-on, Bristol Myers Squibb stock offers a steady 4% yield, with further upside potential.

Both have attracted considerable attention from Wall Street recently.

The company is coming back into the spotlight thanks to recent developments.

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d...

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

These healthcare leaders are unlikely to suspend their dividend programs.

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.